This analysis examines access to, and consumers ability to find information on, a new twice annual long-acting PrEP drug during the first ACA open enrollment period since its approval. Despite the drug widely being considered a major advance, early evidence suggests that insurance coverage and benefit design decisions may create barriers to access.
The Digital Imperative: Why the Future of Surgery Will Be Built on Integrated Intelligence, Not More Devices
The future of surgery will be shaped less by what our tools can do than by how well our systems help humans think when it
